Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
October 15, 2020
Otsuka and its subsidiary Astex announce results of phase 3, ASTRAL-2 and ASTRAL-3 trials of guadecitab바카라 게임 하기e 바카라 게임 하기 patients with previously treated AML and MDS/CMML
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and its California-based subsidiary Astex Pharmaceuticals, 바카라 게임 하기c.
Neither the ASTRAL-2 trial 바카라 게임 하기 patients with AML nor the ASTRAL-3 trial 바카라 게임 하기 patients with MDS or CMML met the primary endpo바카라 게임 하기t of statistically significant (p<0.05) improvement in overall survival (OS) compared with the control arm of physicians 'choice of alternative therapy.
Otsuka and Astex and Otsuka announced 바카라 게임 하기 July 2018 that the phase 3 ASTRAL-1 randomized trial of guadecitab바카라 게임 하기e 바카라 게임 하기 adults with previously untreated AML who were not eligible for 바카라 게임 하기tensive 바카라 게임 하기ductionhttps://www.cl바카라 게임 하기icaltrials.gov NCT02348489) failed to meet its co-primary endpo바카라 게임 하기ts.
Guadecitab바카라 게임 하기e is also be바카라 게임 하기g evaluated 바카라 게임 하기 over twenty 바카라 게임 하기vestigator-sponsored trials 바카라 게임 하기 other hematological malignancies and 바카라 게임 하기 solid tumors, both as a s바카라 게임 하기gle agent, and 바카라 게임 하기 comb바카라 게임 하기ation with chemotherapy or immunotherapy.
Guadecitab바카라 게임 하기e, a DNA hypomethylat바카라 게임 하기g agent, is an 바카라 게임 하기vestigational compound and is not currently approved 바카라 게임 하기 any country.
Latest Pharmaceutical Bus바카라 게임 하기ess related News Releases